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OsteoporosisAbstract As many societies age, primary osteoporosis (PO) is increasingly a major health problem.
Current drug treatments such as alendronate and risedronate have known side effects. We took an
agnostic empirical approach to find PO therapeutic compounds. We examined 13,548,960 probe
data-points from mesenchymal stromal cell (hMSC) lines and found that PGF, DDIT4, and COMP
to be up-regulated, and CHI3L1, down-regulated. We then identified their druggable domains. For
the up-regulated differentially-expressed genes, we used protein–protein interactions to find residue
clusters as binding surfaces. We then employed pharmacophore models to screen 15,407,096 con-
formations of 22,723,923 compounds, which identified (6R,9R)-6-(2-furyl)-9-(1H-indol-3-yl)-2-(tri
fluoromethyl)-5,6,7, 9-tetrahydro-4H[1,2,4]triazolo[5,1],(2S)-N1-[2-[2-(methylamino)-2-oxo-ethyl]p
henyl]-N2-phenylpyrrolidine-1,2-dicarboxamide, and 2-furyl-(1H-indol-3-yl)-methyl-BLAHone as
candidate compounds. For the down-regulated CH13L1, we relied on genome-wide disease signa-
tures to identify (11alpha)-9-fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione and Genistein as
candidate compounds. Our approach differs from previous research as we did not confine our drug
targets to hypothesized compounds in the existing literature. Instead, we allowed the full expression
profile of PO cell lines to reveal the most desirable targets. Second, our differential gene analysis
revealed both up- and down-regulated genes, in contrast to the literature, which has focused on
inhibiting only up-regulated genes. Third, our virtual screening universe of 22,723,923 compounds
was more than 100 times larger than those in the known literature.
 2016 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
As many societies age, primary osteoporosis (PO) is increas-
ingly a major health problem. In the U.S., PO incidence has
logFC AveExpr t P.Value adj.P.Val B
MAB21L2 2.95 6.63 3.64 0.00 0.08 -1.86
XIST 2.85 6.21 2.44 0.03 0.16 -3.86
COL10A1 2.83 7.50 9.39 0.00 0.01 5.26
PGF 2.35 7.61 4.84 0.00 0.04 0.03
IBSP 2.27 7.92 4.57 0.00 0.05 -0.38
DDIT4 2.14 10.35 5.17 0.00 0.04 0.51
NRXN2 2.11 6.04 6.74 0.00 0.02 2.58
MTSS1L 2.08 6.84 9.90 0.00 0.01 5.68
COMP 1.98 8.13 2.05 0.07 0.21 -4.48
PPDPF 1.97 8.63 7.47 0.00 0.01 3.41
RARRES2 1.85 6.49 3.37 0.01 0.09 -2.31
TRIB3 1.84 6.91 4.96 0.00 0.04 0.21
HLA-DRA 1.76 7.62 3.04 0.01 0.11 -2.86
STAT4 1.74 8.62 3.02 0.01 0.11 -2.90
ARHGDIA 1.73 7.54 4.68 0.00 0.05 -0.22
EGR2 1.72 7.21 3.52 0.01 0.08 -2.06
IGFBP2 1.69 9.42 2.37 0.04 0.17 -3.97
SLC27A1 1.68 8.23 5.23 0.00 0.03 0.60
LSP1 1.67 7.14 3.85 0.00 0.07 -1.52
FNDC1 1.65 9.86 1.73 0.11 0.27 -4.96
Figure 1 Up-regulated DEGs using Mendel.
204 C.J. Laisteadily increased from 75 per 100,000 women in the 1950 to
150 per 100,000 women by the 1990s [3]. The most common
drug treatments are generic bisphosphonates such as alen-
dronate and risedronate, due to their low cost [15]. However,
they have well-known upper gastrointestinal side effects and
are associated with atypical fractures of the femur and aseptic
necrosis of the mandible [15]. Recently, a number of research-
ers have sought to identify new therapeutic drugs for PO. For
example, Yasuda et al. [20] focused on cathepsins S and K,
which have selective expression in the extracellular matrix
(ECM). Feder et al. [6] screened a 500-compound library for
purple acid phosphatase inhibitors because elevated phos-
phatases are correlated with osteoporosis. More recently,
Vuorinen et al. [19] screened 202,906 compounds for 17B-
hydroxysteroid dehydrogenase 2 inhibitors, under the assump-
tion that these inhibitors catalyze the inactivation of estradiol
into estrone.
We took a different, novel approach. First, we did not
assume or confine our drug targets to hypothesized com-
pounds in the existing literature. Instead, we allowed the full
expression profile of PO cell lines to reveal the most desirable
targets, subject of course to druggability conditions. Second,
our differential gene analysis of the cell lines revealed both
up- and down-regulated genes, in sharp contrast to the existing
literature, which has focused on inhibiting only up-regulated
genes. Third, we used the new ZINC database of compounds
[7]. With 15,407,096 conformations of 22,723,923 compounds,
this universe is more than 100 times larger than that in Vuori-
nen et al. [19].
In the Section 2, we describe how we used human mes-
enchymal stromal cell (hMSC) cell lines for differential expres-
sion analysis and used virtual-screening on the ZINC database
[7]. In the Section 3, we report four differentially-expressedgenes (DEG): the up-regulated PGF, DDIT4, and COMP
and the down-regulated CHI3L1. This consideration of a
down-regulated gene is a departure from the literature, which
has focused on only up-regulated genes. Finally, we report the
identity of 5 potent candidate compounds under stringent
druggability conditions. We conclude with thoughts on some
remaining limitations and suggest further research directions.
2. Materials and methods
We obtained probe data of hMSC cell lines from the
GSE35936 in the NCBI library [1]. The dataset consisted of
1,354,896 million probes for 54,675 genes in each of 10 cell
lines, of which 5 are age-matched controls. Data were pro-
duced using the Affymetrix U133 Plus 2.0 Array platform.
We undertook differential gene analysis using Mendel [11],
which we developed employing the R language. We then pre-
processed the probe data with Robust Multichip Average
(RMA) analysis. The DEGs were annotated with gene ontol-
ogy, diseased ontology, and KEGG pathways. All this infor-
mation allowed us to identify genes that are significantly up-
or down-regulated, ranked by log fold changes.
The path from significant DEGs to therapeutic compounds
required much filtering. Furthermore, the process for up-
regulated DEGs had to be different than that for down-
regulated ones. While any ligand docked into an up-
regulated DEG domain could be treated as an inhibitor [9],
the same could not be said for a down-regulated DEG.
Instead, we have to explicitly search for agonists for the latter.
For up-regulated genes, we first used EBI’s structured-
based engine to identify druggable protein domains, which
we in turn used to identify clusters of anchor residues over pro-
tein–protein interaction (PPI) surfaces. This was done with
COMP
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Figure 2 (continued)
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Figure 2 Druggable domains of up-regulated DEGs.
Five novel therapeutic compounds for primary osteoporosis 205PocketQuery [9] which ranked the clusters with a composite
score of solvent-accessible surface area (SASA), free energy
(GFC), and sequence conservation, The highest-ranked cluster
was used to build pharmacophore models using Pharmer, a
high-performance search engine based on geometric hashing,
generalized Hough transforms, and Bloom fingerprints [8].
The pharmacophore was then used for virtual screening of
over 22 million compounds using ZINCPharmer [10]. We used
the stringent criteria of a maximum 1 hit per conformation,
maximum 1 hit per molecule, a maximum RMSD of 0.01,
and a maximum of 4 rotatable bonds. Finally, each hit was
characterized with a set of absorption, distribution, metabo-
lism, excretion, and toxicity (ADMET) rules [17].
Our final step was to undertake molecular simulation to
dock the ligands to the protein receptors. To prepare receptors,
we use Chimera [16] to remove the protein’s original ligand,delete its solvent, replace incomplete side chains with
Dunbrack rotamers, add hydrogen and OXT atoms to missing
C-termini (with protonation states for histidine), assign partial
Figure 3 Pathway for PGF effect on osteoclastogenesis.
(a) - Hot region of PGF (human placenta growth factor-1) defined by 
206 C.J. Laicharges from the AMBER ff145B force field with non-
monatomic ion residues using semi-empirical (AMI) with bond
charge correction (BCC).
For down-regulated genes, we again confined our attention
to those with druggable domains. However, we were not
screening for inhibitors, but looking for agonists. We used
the functional connections between genetic perturbation and
drug action to identify bioactive small molecules [12]. We sub-
ject each molecule to the same ADMET rules as for up-
regulated DEGs, and dock them with ligands in the same
manner.
3. Results and discussion
Fig. 1 reports the up- and down-regulated DEGs from Men-
del. LogFC is the value of the contrast in log2 fold-change.
AveExpr is the average log2 expression for that gene across
all arrays and channels. t and P.Value are the usual statistics,
and adj.P.Val adjusts for multiple testing with the Benjamin–
Hochberg method to control for false discovery rate. The B
is the long-odds statistic, measuring the odds that the gene is
differentially expressed.
The most significant up-regulated DEG was MAB21L2, on
chromosome chr4:151,504,181–151,505,261, that is a repressor
of bone morphogenetic protein (BMP)-induced transcription.).
However, as Fig. 2 shows, only three up-regulated DEGs have
druggable domains: PGF (placental growth factor), DDIT4
(DNA-damage-inducible transcript 4), and COMP (cartilage
oligomeric matrix protein).
Fig. 3 shows how PGFmediates osteoclastogenesis [2]. PGF
secreted by osteogenic BMSCs stimulates RANKL (receptor
activator of nuclear factor kappa-B ligand) expression by theseFigure 4 Pathway for DDIT4 effect on osteoblast regulation.same BMSCs, then working with RANKL, PGF also mediates
the differentiation of osteoclast progenitor cells. PGF also sig-
nals directly on these precursors in a positive feedback loop, so
that its pleiotropic actions lead to bone resorption.
DDIT4 is an inhibitor in mTOR signaling in osteoblasts;
see Fig. 4. mTOR is a member of the phosphoinositol kinase
family and a regulator of 1,25(OH)2D (vitamin D) action inresidue clusters, at PPI interfaces.
Residues Number ΔGFC ΔΔGR ΔSASA ΔSASA% SASA Conserv. Evol.Rate
VAL 23 -2.28 1.67 69.72 61 35.19 0.63 0.27
PHE 26 -3.99 3.09 103.29 62.9 36.26 0.9 0.4
VAL 29 -3.28 1.37 69.3 60.7 3.36 0.92 0.72
(b) Residues in hot region of PGF (human placenta growth factor-1) 
defined by residue clusters, at PPI interfaces
Figure 5 Hot region of PGF (human placenta growth factor-1)
defined by residue clusters, at PPI interfaces.
Pharmacophore Class x y z Radius
HydrogenDonor 9.0863.66-11.95 0.5
Hydrophobic 7.7260.01-15.38 1
Hydrophobic 9.4 59.59 -9.04 1
(a) Pharmacophore Classes
(b) Model with anchors shown as space-filled residues and receptors shown as ball-and-stick 
residues
Figure 6 Pharmacophore model of PGF (human placenta
growth factor-1).
Figure 8 PGF docked with (2S)-N1-[2-[2-(methylamino)-2-oxo-
ethyl]phenyl]-N2-phenyl-pyrrolidine-1,2-dicarboxamide.
Five novel therapeutic compounds for primary osteoporosis 207bones, via pS6K1. DDIT4 is also an inhibitor of NFTc1, a
master transcription factor for osteoclastogenesis, via eukary-
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Figure 7 Candidate compounCOMP expresses a noncollagenous glycoprotein that binds
to type I, II, and IX collagen fibers. It has a domain at the
N-terminus, a globular domain at the C-terminus, and 4
epidermal growth factor-like (EGF-like) domains, with 8ADMET 
Results

































ds for up-regulated DEGs.
logFC AveExpr t P.Value adj.P.Val B
CXCL6 -3.68 7.89 -3.08 0.01 0.11 -2.80
CMPK2 -3.67 6.95 -4.21 0.00 0.06 -0.94
RGS4 -3.67 8.65 -3.37 0.01 0.09 -2.32
RPS4Y1 -3.65 7.09 -2.55 0.03 0.15 -3.68
CHI3L1 -3.52 9.21 -3.56 0.00 0.08 -2.00
EIF1AY -3.24 4.16 -2.77 0.02 0.13 -3.32
SCN3A -2.91 4.53 -2.91 0.01 0.12 -3.08
IFIT1 -2.80 8.95 -3.23 0.01 0.10 -2.55
MX1 -2.78 8.66 -2.95 0.01 0.12 -3.01
MEOX2 -2.74 4.53 -8.40 0.00 0.01 4.36
HAPLN1 -2.71 9.21 -2.30 0.04 0.17 -4.08
RSAD2 -2.64 5.93 -2.48 0.03 0.15 -3.79
CXCL1 -2.63 8.07 -3.58 0.00 0.08 -1.97
THBD -2.60 5.99 -4.60 0.00 0.05 -0.34
FGD4 -2.57 5.92 -3.31 0.01 0.10 -2.41
TMEM200A -2.52 7.10 -3.03 0.01 0.11 -2.88
ZNF367 -2.51 5.45 -4.14 0.00 0.06 -1.05
GULP1 -2.48 6.62 -3.19 0.01 0.10 -2.62
IFI27 -2.43 9.04 -2.73 0.02 0.13 -3.39
ZWINT -2.42 6.95 -3.27 0.01 0.10 -2.48
Figure 9 Down-regulated DEGs using Mendel.
208 C.J. Laithrombospondin type 3 repeats (Fig. 2). COMP stabilizes the
collagen fiber network in articular cartilage, tendons, menisci,
and synovial tissue. Up-regulation of COMP, however,
decreases the viability of chondrocytes, which could be a path-
way for PO [5].
Next, we report the results of using PPI to discover regions
of cluster residues for binding to the three druggable up-
regulated PGF, DDIT4, and COMP. Fig. 5 illustrates the
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Genistein
18825330 
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Figure 10 Candidate compoundsand the ligand protein shown with ball-and-sticks. Fig. 6
reports the 3 residues in the cluster model uses the residue clus-
ter at channel A, with 3 residues. GFC is Gibbs free energy and
SASA is solvent accessible surface area. Conserv is the conser-
vation score calculated from the EBI Scorecons server. An
alternative measure of conservation is Evol.Rate, the evolu-
tionary rate computed from Tel Aviv University’s Rate4Site.
With the cluster regions, we successfully built pharma-
cophore models. Fig. 6 illustrates one such model for PGF.ADMET 
Results





















Figure 11 PGCHI3L1 F docked with (11alpha)-9-fluoro-
11,17,21-trihydroxypregn-4-ene-3,20-dione.
Five novel therapeutic compounds for primary osteoporosis 209Finally, Fig. 7 shows the candidate compounds based on
virtual screening using the pharmacophore models. The screen
was able to identify compounds only for PGF. We also report
a number of ADMET screening results. Although not all com-
pounds pass all ADMET screens, all compounds pass most of
the screens.
Of the three compounds, (2S)-N1-[2-[2-(methylamino)-2-o
xo-ethyl]phenyl]-N2-phenyl-pyrrolidine-1,2-dicarboxamide
has the highest pIC50 (3.2), and therefore can be considered
the most potent inhibitor of the up-regulated PGF.
Finally, we were able to dock all three compounds with
PGF. Fig. 8 shows the docking using (2S)-N1-[2-[2-(methyla
mino)-2-oxo-ethyl]phenyl]-N2-phenyl-pyrrolidine-1,2-dicar
boxamide. This has a full fitness of 1167.75 kcal/mol and an
estimated DG at 7.47 kcal/mol.
We now turn from up-regulated to down-regulated DEGs,
shown in Fig. 9. It turns out that only CHI3L1 (chitinase 3-like
1) is druggable. The role of CHI3L1 in osteoporosis is still
uncertain. On the one hand, CHI3L1 promotes the prolifera-
tion of connective tissue. Its silencing with siRNA is known
to lower bone resorption while its transfection decreases the
osteoclast pro-differentiative marker MMP-9 [4]. In this way,
PO might be associated actually with CHI3LI up-regulation.
On the other hand, CHI3LI facilitates bacterial adhesion and
invasion, especially in the epithelial cells. It does this by acti-
vating protein kinase B (AKT) phosphorylation [14]. It is the
excessive production of CHI3L1 that is pathogenic in mucosal
tissues. Therefore, it is also plausible that CHI3L1 down-
regulation is associated with PO, as our probe data revealed.
In short, the exact pathway in which CHI3L1 affects PO needs
to be further investigated.
The disease-gene signature map identified two agonist com-
pounds, reported in Fig. 10. Both are potent, although Genis-
tein is the more potent, with a pIC50 of 4.44. Genistein is
already known to activate peroxisome proliferator-activated
receptors (PPARs), especially gamma forms that regulate bone
mass [13], so it seems quite natural for it to be repurposed for
PO.
Fig. 11 illustrates the docking of (11alpha)-9-fluoro-11,17,
21-trihydroxypregn-4-ene-3,20-dione with CHI3L1. The full
fitness is associated with 1137.60 kcal/mol, with an estimated
DG at 7.40 kcal/mol.4. Conclusion
Our analysis uses an agnostic approach to identify target genes
and their inhibitors and activators, so that we were able to
obtain a comprehensive list of five candidate therapeutic com-
pounds for PO. Interestingly, many of our targets are consis-
tent with the literature, even if current research has not gone
as far as virtual screening of compounds. Furthermore, we
could relax the filtering criteria in many ways, from the thresh-
old log fold-change for determining significant DEGs, to the
criteria for determining targets, identifying druggable
domains, constructing PPI cluster interfaces, modeling phar-
macophores, and finally to screening compounds.
Going forward, the candidate compounds will need biolog-
ical assays and clinical trials, but the lead compounds now
identified could produce a new cocktail of possible therapeutic
drugs for PO.
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